FDA has approved Alimta for the treatment of malignant pleural mesothelioma
The Food and Drug Administration (FDA) today approved Alimta (pemetrexed disodium) for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma - a rare type of cancer. Alimta received a priority review and is designated as an orphan drug. It is the first drug approved for this condition.
For more information about Alimta from the FDA click on the links below:
FDA Press Release in Full
FDA information about Drug
Alimta (pemetrexed for injection)
FDA: Questions and Answers for Alimta (pemetrexed for injection)